Get the Stockscreener App
2.06
0.49%
0.01
Pre-market:
2.06
Neumora Therapeutics Inc stock is traded at $2.06, with a volume of 3.50M.
It is up +0.49% in the last 24 hours and down -81.01% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
See More
Previous Close:
$2.05
Open:
$2.03
24h Volume:
3.50M
Relative Volume:
1.30
Market Cap:
$332.82M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.8128
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-9.65%
1M Performance:
-81.01%
6M Performance:
-81.74%
1Y Performance:
-85.54%
1-Day Range:
$2.01
$2.125
1-Week Range:
$2.00
$2.32
52-Week Range:
$1.83
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.06 | 332.82M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Neumora shares slump after depression drug fails in key trial - MSN
William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
William Blair Reiterates "Outperform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MSN
Neumora Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Neumora Therapeutics's SWOT analysis: navacaprant setback tests resilience of CNS-focused biotech stock - Investing.com
Neumora’s Major Setback with Navacaprant Program: Industry Reacts - Zenopa
Stock Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora stock faces skepticism after failed trial, but BofA remains optimistic - Investing.com Canada
Bank of America Cuts Neumora Therapeutics (NASDAQ:NMRA) Price Target to $7.00 - MarketBeat
What is William Blair's Estimate for NMRA FY2029 Earnings? - MarketBeat
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - MSN
Neumora shares look oversold after 80% drop, says Mizuho - Yahoo Finance
Neumora Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Neumora Therapeutics stock reiterated at Buy by analyst following KOASTAL-1 result - Investing.com Canada
Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops - MSN
Mizuho reiterates Outperform on Neumora Therapeutics stock post navacaprant data - Investing.com Canada
Neumora’s KOSTAL-1 Study of Navacaprant Yields Disappointing Results - Contract Pharma
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression - Yahoo Finance
Neumora fails in late-stage trial for depression therapy - MSN
Neumora shares sink following Phase III flop in MDD - MSN
Neumora tanks as KOASTAL-1 study of navacaprant misses - The Pharma Letter
Neumora Therapeutics (NASDAQ:NMRA) Hits New 1-Year LowTime to Sell? - MarketBeat
Neumora Stock Dives After Study Failure - The Wall Street Journal
Neumora Therapeutics, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
New Year’s Hangover: Neumora’s Phase III Failure In Depression Surprises - News & Insights
Neumora plummets on depression drug data - BioPharma Dive
Results are in for a new depression drug trial, and they're cratering this stock - Yahoo Finance
RBC Capital cuts Neumora Therapeutics stock rating to Sector Perform By Investing.com - Investing.com Canada
Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial - MSN
Neumora's depression drug misses main goal in study By Investing.com - Investing.com South Africa
Mass. biotech stock plunges after depression drug fails late-stage trial - The Business Journals
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals - MSN
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):